Previous 10 | Next 10 |
2024-03-29 09:59:07 ET Summary The diabetes and obesity markets are large and growing, with an estimated total long-term addressable market of $100 billion in the US alone. Denmark's Novo Nordisk and US-based Eli Lilly are leading pharmaceutical companies in the development of GLP...
Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the closing of its previo...
2024-03-25 23:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-22 05:36:43 ET More on Stevanato Group Stevanato: Destocking And Valuation Risk (Rating Downgrade) Stevanato announces $300M public offering of ordinary shares Booming weight-loss drug market to lift “pick-and-shovel” plays: Jefferies Se...
Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the pricing of its upsize...
2024-03-20 17:19:47 ET More on Stevanato Group Stevanato: Destocking And Valuation Risk (Rating Downgrade) Stevanato Group S.p.A. (STVN) Q4 2023 Earnings Call Transcript Booming weight-loss drug market to lift “pick-and-shovel” plays: Jefferies ...
Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the launch of an underwri...
2024-03-11 22:24:24 ET Summary Stevanato's peers decided to lower sales growth estimates in 2024 due to clients' destocking activities. The company's EBITDA and net profit declined due to start-up costs and an unfavorable exchange rate effect. Stevanato's valuation looks full ...
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the KeyBanc Capital Markets Virtual Life Sciences & MedTe...
2024-03-07 14:41:06 ET Stevanato Group S.p.A. (STVN) Q4 2023 Earnings Conference Call March 7, 2024 08:30 ET Company Participants Lisa Miles - Senior Vice President of Investor Relations Franco Stevanato - Executive Chairman Marco Dal Lago - Chief Financial Offic...
News, Short Squeeze, Breakout and More Instantly...
Stevanato Group S.p.A. Company Name:
STVN Stock Symbol:
NYSE Market:
Stevanato Group S.p.A. Website:
2024-07-04 19:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-24 21:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Cisterna’s site is the first to implement premium solutions outside the Group’s headquarters in Piombino Dese to meet the growing demand for biopharmaceuticals, such as GLP-1s in Europe. Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containme...